<DOC>
	<DOCNO>NCT00653055</DOCNO>
	<brief_summary>To compare rate extent absorption cabergoline 0.5 mg tablet ( test ) versus Dostinex ( reference )</brief_summary>
	<brief_title>Bioequivalence Study Cabergoline Tablets Dostinex Under Fasting Conditions</brief_title>
	<detailed_description>To compare rate extent absorption cabergoline 0.5 mg tablet ( test ) versus Dostinex ( reference ) administer 2 x 0.5 mg tablet fast condition .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<criteria>Subjects females male , smoker nonsmoker 18 year age old Subjects read , sign date Informed Consent Form prior study procedure Subjects must complete screening procedure within 28 day prior administration study medication Breast feed female subject Clinically significant abnormality find medical screen Any clinically significant gastrointestinal pathology unresolved gastrointestinal symptom susceptible interfere absorption drug Clinically significant illness within 4 week administration study medication Abnormal laboratory test judge clinically significant ECG abnormality vital sign abnormality screen Subjects BMI great equal 30.0 History allergic reaction cabergoline ergot derivative Any food allergy , intolerance , restriction , special diet opinion medical subinvestigator , contraindicate subject 's participation study Positive urine drug screen screen Positive test hepatitis B , hepatitis C HIV screen Positive urine pregnancy test screening ( performed female ) Use investigational drug participation investigational study , within 30 day prior administration study medication Donation plasma ( 500 mL ) within 7 day donation significant loss whole blood ( 450 mL ) within 56 day prior administration study medication History significant alcohol abuse within six month screen visit indication regular use two unit alcohol per day History drug abuse use illegal drug : use soft drug ( marijuana , pot ) within 3 month screen visit hard drug ( cocaine , PCP , crack ) within 1 year screen visit Subjects take prescription medication within 14 day prior administration study medication overthecounter product within 7 day prior administration study medication , except topical product without systemic absorption Female subject childbearing potential unprotected sexual intercourse nonsterile male partner ( i.e . male sterilize vasectomy last 6 month ) within 14 day prior study drug administration . The acceptable method contraception condom + spermicide ( least 14 day prior study drug administration ) , diaphragm + spermicide ( least 14 day prior study drug administration ) intrauterine contraceptive device ( place least 4 week prior study drug administration Subjects take drug know induce inhibit hepatic drug metabolism within 30 day prior administration study medication Subjects undergone clinically significant surgery within 4 week prior administration study medication Any reason , opinion medical subinvestigator , would prevent subject participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Cabergoline</keyword>
	<keyword>Fasting</keyword>
</DOC>